Osborne Partners Capital Management LLC Buys 50 Shares of Amgen Inc. (NASDAQ:AMGN)

Osborne Partners Capital Management LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,475 shares of the medical research company’s stock after acquiring an additional 50 shares during the period. Osborne Partners Capital Management LLC’s holdings in Amgen were worth $3,251,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter worth about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 3rd quarter worth approximately $29,000. Matrix Trust Co acquired a new position in Amgen during the 3rd quarter worth approximately $36,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the third quarter worth $56,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMGN. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Citigroup decreased their price objective on Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Barclays upped their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $314.00.

Amgen Stock Performance

AMGN opened at $285.42 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a fifty day simple moving average of $271.06 and a 200 day simple moving average of $304.53. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $153.42 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 2.85 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. Research analysts expect that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.34%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.